Menu

Recent Interviews

Jared Scharf, CEO, Desert Gold Ventures Inc.

Jared Scharf
CEO | Desert Gold Ventures Inc.
4770 72nd St,, V4K 3N3 Delta (CAN)

jared.scharf@desertgold.ca

Desert Gold Ventures CEO Jared Scharf on West Africa and its potential


Stephan Dorfmeister, Finance Department, Deep Nature Project GmbH

Stephan Dorfmeister
Finance Department | Deep Nature Project GmbH
Untere Hauptstraße 168, 7122 Gols (AT)

office@deep-nature.at

+43 681 10139055

Like Aurora Cannabis and Canopy Growth, Deep Nature Project GmbH focuses on value chain


Alison Coutts, Executive Chairman, Memphasys Ltd.

Alison Coutts
Executive Chairman | Memphasys Ltd.
30 Richmond Road, 2140 Homebush West (AUS)

alison.coutts@memphasys.com

+61 2 8415 7300

Memphasys Executive Chairman Alison Coutts on in vitro fertilisation (IVF)


02. June 2020 | 05:58 CET

Memphasys, Moderna, Paion - Investments in solutions with potential

  • Healthcare

Biotech companies around the world employ scientists and physicians to study the causes of diseases. The research and development of medical products and solutions usually involves a large number of tests and takes a correspondingly long time. The longer and more extensive this process is, the more capital these companies require from investors. In the race to bring to market preparations or products that improve people's well-being or fulfill desires, the providers of solutions usually have great sales potential and investors may be bought out through a takeover.

time to read: 1 minutes by Mario Hose


 

Biological separation

Memphasys from Australia has developed a solution for parents with a desire to have children, which allows high-quality sperm to be biologically separated from the man's seminal fluid. The product from Memphasys is called FELIX and increases the chances of success of artificial insemination. The company thus serves a growth market, as more and more couples are deciding to start their professional career first when planning their lives. With increasing age, however, the chance of success of a natural pregnancy decreases and the advice of experts is sought.

In the second half of 2020, FELIX is to be launched in various countries around the globe. The biological separation process not only works with humans, but can also be used with mammals in the future - also a huge market, according to Alison Coutts Memphasys' market capitalization is currently AUD 52 million at AUD 0.07 per share. The shares are also traded in Germany.

Covid-19 vaccine hope

The US biotech company Moderna is in the public eye as it is working on a vaccine against Covid-19, and since the outbreak of the Corona Pandemic, the value of its shares has already risen by around 200%, and at USD 62 per share, its market value is over USD 23 billion. In a recent announcement, the company provided information on the development status. The mid-stage clinical trials have started with 600 patients. Moderna has been researching a vaccine candidate since March 2020 and people are hopeful that a vaccine will provide a way out of the Corona Crisis.

Approval for anaesthetics

The Paion shares are also hot at the moment. The company may receive approval for the anesthetic Remimazolam from the US Food and Drug Administration (FDA) in the coming months. "In 2020, Paion's focus will be on evaluating the European Phase III study in general anaesthesia, the regulatory approval process in the US, Europe and other regions, the development of the supply chain and commercial manufacturing of Remimazolam, as well as the market preparation and launch of Remimazolam in different territories," the company announced. Paion's most recent liquidity was approximately EUR 18 million and its share price of EUR 2.29 represents a market value of EUR 143 million.


Conflict of interest & risk note

In accordance with §34b WpHG we would like to point out that Apaton Finance GmbH as well as partners, authors or employees of Apaton Finance GmbH may hold shares in the aforementioned companies and that there may therefore be a conflict of interest. Further details can be found in our Conflict of Interest & Risk Disclosure.


Related comments:

18. June 2020 | 08:40 CET

BioNTech, Evotec, EXMceuticals - which stocks have the potential to double?

  • Healthcare

Experienced investors assume that the DAX, Germany's leading index, will still reach new highs in 2020. One of the best-known supporters of this scenario is the asset manager Dr. Jens Ehrhardt. Rising markets are supported by the measures taken by central banks and politicians - it is de facto the consequence of the increase in the money supply. This expected development will be of particular interest to those investors who have so far been on the sidelines and have to position themselves or reallocate.

Read

16. June 2020 | 06:30 CET

Gilead, Teva, XPhyto - Global marketing potential

  • Healthcare

The best business models solve problems and are scalable. In this context, the healthcare sector is particularly interesting. The world's population has recently reached 7.8 billion people and for this reason solutions can meet a large potential market with users. Cross-border solutions are needed not only for pandemics, but also for diseases that are not mentioned in the mass media but are nevertheless of great importance. A successful market launch is of equal interest to those affected and investors.

Read

26. May 2020 | 07:43 CET

BioNTech, Evotec, XPhyto - will the next rally start?

  • Healthcare

Germany's leading index DAX closed the previous day at 11,391 points, its highest level since March 2020. At the beginning of the week the index of the 30 largest German companies gained 317 points compared to Friday, representing a gain of 2.87%. In the USA Wall Street remained closed on Monday due to the Memorial Day. As is well known, the stock market is where the future is traded and for this reason investors are already investing in the prospects of companies in the period following the Corona Pandemic. A rally has begun.

Read